1M6MYTD1Y5YMAX
Loading quotes...
Forecast
The analysts' average price target is €20.28 (+53.52%). The median is €20.28 (+53.52%).
| Buy |
2 |
| Hold |
0 |
| Sell |
0 |
News Go to news feed
There is currently no news available for this company. We are working on adding more providers to change this.
Financials
| (EUR) | Jun 2026 | |
|---|---|---|
| Revenue | 5.53M | - |
| Gross profit | 5.53M | - |
| Net profit | -58.93M | - |
| EBITDA | -55.92M | - |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €1.74B |
Number of shares | 128.19M |
52-week high/low | €19.57 - €9.49 |
| Dividends | No |
Beta | -0.14 |
P/E ratio | -14.88 |
PEG ratio | -0.15 |
P/B ratio | 4.43 |
P/S ratio | 149.33 |
Company profile
| Name | GENERATE BIOMEDICINES |
| CEO | Michael T. Nally |
| Employees | 312 |
Deep Dive
Discover assets
Shareholders of GENERATE BIOMEDICINES also invest in the following assets
